ABBV vs MRNA
AbbVie (ABBV) and Moderna (MRNA) compared side by side. AbbVie (ABBV) is larger, with a market cap of $504.8B versus $79.9B for Moderna, about 6.3 times the size. MRNA returned +662.3% over the past year including dividends, versus +28.9% for ABBV, through October 23, 2026..
Head to head
| Metric | ABBV | MRNA |
|---|---|---|
| Market cap | $504.8B | $79.9B |
| P/E (TTM) | 80.7x | — |
| Forward P/E | 17.6x | -43.6x |
| Revenue (TTM) | $64.4B | $2.2B |
| Revenue growth | 10.2% | 2.1% |
| Gross margin | 72.8% | -66.0% |
| Operating margin | 40.0% | -557.9% |
| Free cash flow | $18.2B | -$1.2B |
| Dividend yield | 2.42% | None |
| 1-year return | +28.9% | +662.3% |
| 5-year return (annual) | +25.6% | -9.3% |
| Max drawdown | -45% | -95% |
| FI Handbook grade | B | F |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
$0
$10.0K
$20.0K
20222023202420252026
ABBV vs MRNA FAQ
Which is bigger, ABBV or MRNA?
AbbVie (ABBV) is larger, with a market cap of $504.8B versus $79.9B for Moderna, about 6.3 times the size.
Which stock performed better over the past year, ABBV or MRNA?
MRNA returned +662.3% over the past year including dividends, versus +28.9% for ABBV, through October 23, 2026.
Which pays a higher dividend, ABBV or MRNA?
ABBV yields 2.42%; MRNA does not pay a dividend.